Cleavable scFv-Transferrin Fusion for Selective BBB Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current monoclonal antibodies face low bioavailability in the brain due to the restrictive nature of the blood-brain barrier, limiting their therapeutic efficacy in treating neurodegenerative disorders, and existing methods to enhance delivery are either invasive, non-selective, or inefficient.
Innovation Solution
Development of a single-chain variable fragment (scFv) fusion protein (RNAT26) that utilizes receptor-mediated transcytosis by binding to the transferrin receptor, with engineered linkers for controlled release and targeted delivery of therapeutic agents across the blood-brain barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If monoclonal antibodies are administered systemically to treat CNS disorders, then therapeutic coverage is achieved, but brain bioavailability remains extremely low (less than 0.1% of injected dose)
Solution Approach 1:
The patent uses transferrin as an intermediary molecule to facilitate antibody transport across the BBB. The transferrin-antibody conjugate exploits the endogenous transferrin receptor-mediated transcytosis pathway, allowing the antibody to 'hitchhike' across the barrier without direct disruption of BBB integrity. This mediator approach achieves brain delivery while maintaining physiological conditions.
Solution Approach 2:
The patent modifies the physical-chemical parameters of the therapeutic antibody by conjugating it with transferrin. This changes the molecular characteristics of the antibody, enabling it to interact with transferrin receptors on BBB endothelial cells and undergo receptor-mediated transcytosis, thereby achieving brain penetration that is impossible for native antibodies.
2Quantity of substance
If BBB disruption methods (mannitol, focused ultrasound, tight junction disruption) are used to enhance antibody delivery, then brain exposure increases, but selective delivery is lost and toxic blood components can enter the brain
Solution Approach 1:
The transferrin-conjugated antibody uses transferrin receptors as a selective gateway through the BBB. This receptor-mediated pathway provides molecular-level selectivity, allowing only the conjugate to pass through endothelial cells via transcytosis, while excluding non-specific blood components and potential toxins.
Solution Approach 2:
The patent converts the normally harmful restrictive nature of the BBB into a beneficial selective filter. By exploiting the endogenous transferrin receptor system that normally transports iron, the invention turns the barrier's selectivity against itself, using the same mechanism that protects the brain to now deliver therapeutic agents selectively without compromising brain safety.
3Quantity of substance
If bisspecific antibodies are used to achieve BBB penetration via RMT, then brain delivery improves to about 1% of injected amount, but manufacturing complexity and cost increase significantly
Solution Approach 1:
The patent segments the therapeutic function from the BBB penetration function. The antibody retains its full therapeutic structure and function, while a separate transferrin moiety provides the BBB crossing capability. This segmentation allows each component to be optimized independently and simplifies manufacturing compared to bispecific antibodies, which require complex dual-specificity engineering.
Solution Approach 2:
The patent merges the therapeutic antibody with transferrin through conjugation to create a unified delivery system. This combination leverages the high affinity of transferrin for its receptor to achieve efficient BBB transport, while maintaining the antibody's therapeutic integrity. The merger provides a simpler manufacturing pathway than bispecific antibodies, as it uses established conjugation chemistry rather than complex protein engineering.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the bioavailability of therapeutic antibodies in the brain, providing selective and efficient delivery of scFv fusion proteins to target proteins like amyloid beta, tau, and alpha-synuclein, improving treatment efficacy for neurodegenerative disorders.
Implementation Method 1
Macromolecules such as monoclonal antibodies ("mAbs") can utilize three types of vesicles to traverse brain endothelial cells: (i) clathrin-coated vesicles, (ii) caveolae domains generated from lipid rafts, and (iii) macropinocytotic vesicle. For transcytosis of large molecules, which primarily uses clathrin-coated vesicles, a receptor is required for uptake and trafficking across the brain endothelial cells. This process has been termed "receptor-mediated transcytosis" ("RMT").
Data Source
AI summary
Antibodies can treat neurodegenerative disorders (NDs) caused by misfolded proteins. Still, the blood-brain-barrier (BBB) resists their entry, a barrier that can be reduced by scFv instead of whole antibody and conjugating it with transferrin protein to induce transcytosis. While the scFv binds variable heavy and light chains with a non-cleavable linker, a cleavable linker between the scFv and transferrin protein can reduce exocytosis, enhancing the activity of the scFv.